Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
Phase I/II Trial of Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed Glioblastoma Multiforme
Sponsor: Feinstein Institute for Medical Research
Listed as NCT01811498, this PHASE1/PHASE2 trial focuses on Brain Tumor and Glioblastoma Multiforme and remains completed. Sponsored by Feinstein Institute for Medical Research, it has been updated 12 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2022 — Feb 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2021 — Jul 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2019 — Oct 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Jun 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Feb 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Feinstein Institute for Medical Research
- Northwell Health
For direct contact, visit the study record on ClinicalTrials.gov .